KLK3 and prostate carcinoma: With the extension of treatment time, almost all prostate cancer patients initially sensitive to ADT will eventually develop hormone resistance, as well as the upregulation of prostate-specific antigen (PSA), a gene downstream of androgen receptor, which means the disease progression into castration-resistant prostate cancer [8].